William Blair Reiterates "Outperform" Rating for Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at William Blair in a research report issued to clients and investors on Friday,RTT News reports. William Blair also issued estimates for Atea Pharmaceuticals' Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals Price Performance

Shares of NASDAQ:AVIR remained flat at $2.92 during trading hours on Friday. 343,452 shares of the company's stock were exchanged, compared to its average volume of 281,364. Atea Pharmaceuticals has a 52 week low of $2.75 and a 52 week high of $4.15. The business's 50-day moving average is $3.14 and its 200 day moving average is $3.33. The stock has a market cap of $246.63 million, a PE ratio of -1.41 and a beta of 0.18.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Equities research analysts anticipate that Atea Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Atea Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its stake in Atea Pharmaceuticals by 5.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 73,883 shares of the company's stock valued at $248,000 after purchasing an additional 3,882 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of Atea Pharmaceuticals by 31.5% in the 4th quarter. ProShare Advisors LLC now owns 25,733 shares of the company's stock valued at $86,000 after buying an additional 6,163 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Atea Pharmaceuticals by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company's stock valued at $2,209,000 after buying an additional 9,370 shares during the last quarter. Renaissance Technologies LLC raised its stake in Atea Pharmaceuticals by 0.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,216,600 shares of the company's stock worth $4,076,000 after acquiring an additional 9,500 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Atea Pharmaceuticals by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 45,391 shares of the company's stock worth $152,000 after acquiring an additional 9,865 shares in the last quarter. Hedge funds and other institutional investors own 86.67% of the company's stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.